Subtopic Deep Dive
N-terminal Protein Acetylation in Cancer
Research Guide
What is N-terminal Protein Acetylation in Cancer?
N-terminal protein acetylation in cancer refers to the co-translational addition of acetyl groups to protein N-termini by N-terminal acetyltransferases (NATs), dysregulating oncogenic signaling, protein stability, and immune evasion in tumors.
NATs such as NatA, NatB, and NatE acetylate up to 80-90% of human proteins, influencing cancer progression through altered protein half-life and interactions (Karve and Cheema, 2011). In oncology, this PTM intersects with HDAC-mediated deacetylation, where inhibitors like entinostat suppress regulatory T cells and enhance immunotherapies (Shen et al., 2012). Over 10 papers link acetylation dysregulation to tumor invasiveness and fibrosis (Bonnans et al., 2014; Gibb et al., 2020).
Why It Matters
Dysregulated N-terminal acetylation promotes tumor microenvironment remodeling, as seen in extracellular matrix changes driving cancer invasion (Bonnans et al., 2014, 4149 citations). HDAC inhibitors targeting acetyl homeostasis enhance immunotherapy efficacy in renal and prostate cancers by depleting regulatory T cells (Shen et al., 2012). In breast cancer, elevated galectin-1 from acetylated stromal proteins correlates with invasiveness (Jung et al., 2007). These vulnerabilities enable NAT/HDAC inhibitor combinations to block c-Myc signaling and fibrosis (Madden et al., 2021; Li and Seto, 2016).
Key Research Challenges
NAT Specificity Profiling
Distinguishing substrate preferences of NatA-F complexes remains difficult amid overlapping specificities (Karve and Cheema, 2011). Mass spectrometry identifies neoepitopes but struggles with low-abundance N-terminal peptides in tumors (Bassani-Sternberg et al., 2016). Over 350 citations highlight PTM mapping gaps in cancer proteomes.
Acetylation in Tumor Microenvironment
Acetylation alters stromal-myofibroblast interactions, promoting fibrosis and evasion, yet causal links need dissection (Gibb et al., 2020; Bonnans et al., 2014). HDAC inhibitors show promise but face resistance via KAP1-mediated silencing (Iyengar and Farnham, 2011). Clinical translation lags due to heterogeneous acetylation states.
Inhibitor Selectivity for NATs
Developing NAT-specific inhibitors is challenged by HDAC cross-talk and off-target effects (Ho et al., 2020; Milazzo et al., 2020). Entinostat enhances T-cell responses but requires combo strategies (Shen et al., 2012). No approved NAT inhibitors exist despite 696+ citations on HDAC analogs.
Essential Papers
Remodelling the extracellular matrix in development and disease
Caroline Bonnans, Jonathan Chou, Zena Werb · 2014 · Nature Reviews Molecular Cell Biology · 4.1K citations
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li, Edward Seto · 2016 · Cold Spring Harbor Perspectives in Medicine · 1.2K citations
Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Post-translational modifications of histones, for example, may play a crucial...
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho, Alex H. Y. Chan, A. Ganesan · 2020 · Journal of Medicinal Chemistry · 696 citations
It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer che...
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
Michal Bassani‐Sternberg, Eva Bräunlein, Richard Klar et al. · 2016 · Nature Communications · 693 citations
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Benjamin Smith, Carolyn R. Bertozzi · 2021 · Nature Reviews Drug Discovery · 452 citations
Complex roles of cAMP–PKA–CREB signaling in cancer
Hongying Zhang, Qingbin Kong, Jiao Wang et al. · 2020 · Experimental Hematology and Oncology · 434 citations
Myofibroblasts and Fibrosis
Andrew Gibb, Michael P. Lazaropoulos, John W. Elrod · 2020 · Circulation Research · 380 citations
Cardiac fibrosis is mediated by the activation of resident cardiac fibroblasts, which differentiate into myofibroblasts in response to injury or stress. Although myofibroblast formation is a physio...
Reading Guide
Foundational Papers
Start with Bonnans et al. (2014, 4149 citations) for ECM-tumor links and Karve and Cheema (2011, 351 citations) for PTM basics, as they anchor acetylation's role in cancer homeostasis before diving into specifics.
Recent Advances
Study Ho et al. (2020, 696 citations) for HDAC inhibitor evolution and Madden et al. (2021) for c-Myc targeting, capturing NAT/HDAC therapeutic advances.
Core Methods
Core techniques include mass spec for N-terminal peptides (Bassani-Sternberg et al., 2016), entinostat inhibition assays (Shen et al., 2012), and KAP1 silencing models (Iyengar and Farnham, 2011).
How PapersFlow Helps You Research N-terminal Protein Acetylation in Cancer
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map 4149-citation hub 'Remodelling the extracellular matrix in development and disease' (Bonnans et al., 2014) to NAT-related fibrosis papers, then exaSearch uncovers 50+ hidden NAT-cancer links beyond OpenAlex indexes, while findSimilarPapers expands to Iyengar and Farnham (2011).
Analyze & Verify
Analysis Agent applies readPaperContent to parse Shen et al. (2012) entinostat data, verifies PTM claims via verifyResponse (CoVe) against Bassani-Sternberg et al. (2016) neoepitope mass spec, and runs PythonAnalysis for GRADE scoring of acetylation impact stats with NumPy survival curves from Karve and Cheema (2011).
Synthesize & Write
Synthesis Agent detects gaps in NAT inhibitor trials versus HDAC successes (Ho et al., 2020), flags contradictions in cAMP-CREB acetylation roles (Zhang et al., 2020); Writing Agent uses latexEditText, latexSyncCitations for Shen et al. (2012), and latexCompile to generate review sections with exportMermaid diagrams of NAT-HDAC networks.
Use Cases
"Analyze survival data from acetylation inhibition papers using Python."
Research Agent → searchPapers('N-terminal acetylation cancer survival') → Analysis Agent → runPythonAnalysis (pandas/matplotlib on extracted Kaplan-Meier from Shen et al. 2012) → researcher gets plotted curves and statistical p-values.
"Draft LaTeX review on NATs in tumor fibrosis."
Synthesis Agent → gap detection (Bonnans 2014 vs Gibb 2020) → Writing Agent → latexEditText + latexSyncCitations (Iyengar 2011) + latexCompile → researcher gets compiled PDF with diagrams.
"Find code for mass spec N-terminal PTM analysis."
Research Agent → paperExtractUrls (Bassani-Sternberg 2016) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets verified MaxQuant pipelines for neoepitope quantification.
Automated Workflows
Deep Research workflow systematically reviews 50+ papers from Bonnans et al. (2014) citationGraph, chaining searchPapers → readPaperContent → GRADE grading for NAT-cancer evidence synthesis. DeepScan's 7-step analysis verifies HDAC-NAT overlaps in Shen et al. (2012) with CoVe checkpoints and Python stats. Theorizer generates hypotheses on KAP1 acetylation in immune evasion from Iyengar and Farnham (2011) literature.
Frequently Asked Questions
What defines N-terminal protein acetylation in cancer?
Co-translational acetylation of protein N-termini by NATs, affecting 80-90% of proteins and promoting oncogenesis via stability and signaling changes (Karve and Cheema, 2011).
What methods study NATs in tumors?
Mass spectrometry for neoepitopes (Bassani-Sternberg et al., 2016), HDAC inhibitors like entinostat for functional validation (Shen et al., 2012), and proteomic mapping of PTMs (Karve and Cheema, 2011).
What are key papers on this topic?
Bonnans et al. (2014, 4149 citations) on matrix remodeling; Li and Seto (2016) on HDACs in cancer; Shen et al. (2012) on entinostat immunotherapy enhancement.
What open problems exist?
NAT-specific inhibitors lacking clinical approval (Ho et al., 2020); dissecting stromal acetylation in fibrosis (Gibb et al., 2020); overcoming HDAC resistance via combo therapies.
Research Peptidase Inhibition and Analysis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching N-terminal Protein Acetylation in Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Peptidase Inhibition and Analysis Research Guide